Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential Pathways of Testing After First-Trimester Screening for Trisomy 21

1 Oct 2004

Abstract excerpt

OBJECTIVE: To evaluate the performance and use of second-trimester multiple-marker maternal serum screening for trisomy 21 by women who had previously undergone first-trimester combined screening (nuchal translucency, pregnancy-associated plasma protein A, and free beta-hCG), with disclosure of risk estimates. METHODS: In a multicenter, first-trimester screening study sponsored by the National Institute of Child...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Assisted Reproductive Technology and Twin Pregnancy
Share to Gestational Trophoblastic Disease Studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15458882
DOI: 10.1097/01.aog.0000139832.79658.b9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential Pathways of Testing After First-Trimester Screening for Trisomy 21PMID 15458882Read ↗

Accuracy of first‐trimester combined test in screening for trisomies 21, 18 and 13Semantic proximity Read ↗

First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestationSemantic proximity Read ↗

Prenatal diagnostic testing and atypical chromosome abnormalities following combined first‐trimester screening: implications for contingent models of non‐invasive prenatal testingSemantic proximity Read ↗

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

First trimester screening for other trisomies than trisomy 21, 18, and 13Semantic proximity Read ↗

First-Trimester Screening for Trisomies 21 and 18Semantic proximity Read ↗

Screening for Chromosomal Abnormalities by First Trimester Combined Screening and Noninvasive Prenatal TestingSemantic proximity Read ↗

Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

Nearly a third of abnormalities found after first‐trimester screening are different than expected:10‐year experience from a single centerSemantic proximity Read ↗

First‐trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional studySemantic proximity Read ↗

Prospective validation of first‐trimester combined screening for trisomy 21Semantic proximity Read ↗

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.